Anthony DelConte
Lipocine Inc. · Chief Medical Director, Lipocine, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anthony DelConte as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 02:19 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04685993 · A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 TrialLipocine Inc. · completed · NASH - Nonalcoholic Steatohepatitis · study director
- Ph2NCT04134091 · The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic SteatohepatitisLipocine Inc. · completed · Nonalcoholic Steatohepatitis (NASH) · study director
- Ph3NCT03868059 · Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal MenLipocine Inc. · completed · Hypogonadism, Male · study director
- Ph3NCT03242590 · Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).Lipocine Inc. · completed · Hypogonadism, Male · study director
- Ph3NCT03242408 · Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021)Lipocine Inc. · completed · Hypogonadism, Male · study director
- Ph3NCT02081300 · Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or HypogonadismLipocine Inc. · completed · Male Hypogonadism · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 02:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 02:19 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- 52 citationsRCR 2.7
- Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North american Levonorgestrel Study Group (NALSG).Am J Obstet Gynecol · 199941 citationsRCR 1.9
- The effects on ovarian activity of a monophasic oral contraceptive with 100 microg levonorgestrel and 20 microg ethinyl estradiol.Am J Obstet Gynecol · 199933 citationsRCR 1.5
- A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder.Int J Clin Pract · 200833 citationsRCR 1.5
- A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 micrograms/20 micrograms versus triphasic norethindrone/ethinylestradiol 500-750-1000 micrograms/35 micrograms: a multicenter, randomized, open-label study.Eur J Contracept Reprod Health Care · 199923 citationsRCR 1.1
- Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men.J Cardiovasc Pharmacol Ther · 202122 citationsRCR 1.7
- Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial.Hepatology · 202516 citationsRCR 5.8
- 12 citationsRCR 0.7
- Effects of low-dose monophasic levonorgestrel with ethinyl estradiol preparation on serum lipid levels: A twenty-four month clinical trial.Am J Obstet Gynecol · 19997 citationsRCR 0.3
- Using a low-dose contraceptive in women 35 years of age and over: 20 microg estradiol/100 microg levonorgestrel.Contraception · 20026 citationsRCR 0.2